Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study.

Huiqiang Huang Rong TaoSiguo HaoYu YangHong CenHui ZhouYe GuoLiqun ZouJunning CaoYunhong HuangJie JinLiling ZhangHaiyan YangXiaojing XingHuilai ZhangYan-Yan LiuKaiyang DingQinzhou QiXiaoli ZhuDan ZhuSiyuan WangTeng FangHangjun DaiQingmei ShiJason Yang

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)

Sugemalimab showed robust and durable antitumor activity in R/R ENKTL. Treatment was well tolerated with expected safety profile for this drug class.

Keyphrases

phase ii study
open label
combination therapy
acute lymphoblastic leukemia
locally advanced
acute myeloid leukemia
hodgkin lymphoma
randomized controlled trial
radiation therapy
squamous cell carcinoma
clinical trial
emergency department
cross sectional
study protocol
drug induced